Tempest Therapeutics (NASDAQ:TPST) Raised to “Hold” at Wall Street Zen

Tempest Therapeutics (NASDAQ:TPST) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently issued reports on TPST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Monday, December 29th. Zacks Research raised shares of Tempest Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Tempest Therapeutics Trading Down 12.5%

NASDAQ:TPST opened at $1.96 on Friday. The firm has a 50-day moving average price of $2.11 and a two-hundred day moving average price of $4.50. Tempest Therapeutics has a twelve month low of $1.50 and a twelve month high of $12.23. The company has a market capitalization of $28.11 million, a P/E ratio of -0.30 and a beta of -2.00.

Tempest Therapeutics (NASDAQ:TPST) last posted its earnings results on Monday, March 30th. The company reported ($0.62) earnings per share for the quarter, meeting the consensus estimate of ($0.62). On average, equities research analysts predict that Tempest Therapeutics will post -1.39 earnings per share for the current year.

Insider Activity

In related news, CEO Matthew Angel bought 231,482 shares of the firm’s stock in a transaction that occurred on Tuesday, March 24th. The shares were acquired at an average cost of $2.16 per share, with a total value of $500,001.12. Following the completion of the transaction, the chief executive officer owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 6.28% of the company’s stock.

Institutional Investors Weigh In On Tempest Therapeutics

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of Tempest Therapeutics by 20.8% in the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after acquiring an additional 27,952 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Tempest Therapeutics in the fourth quarter worth approximately $33,000. Finally, Sabby Management LLC acquired a new stake in shares of Tempest Therapeutics in the fourth quarter worth approximately $513,000. 22.52% of the stock is owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.